Amitriptyline at Low-Dose and Titrated for Irritable Bowel Syndrome as Second-Line Treatment in primary care (ATLANTIS): a randomised, double-blind, placebo-controlled, phase 3 trial
Open accessThe DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Most patients with irritable bowel syndrome (IBS) are managed in primary care. When first-line therapies for IBS are ineffective, the UK National Institute for Health and Care Excellence guideline suggests considering low- dose tricyclic antidepressants as second-line treatment, but their effectiveness in primary care is unknown, and they are infrequently prescribed in this setting. METHODS: This randomised, double-blind, placebo-controlled trial (Amitriptyline at Low-Dose and Titrated for Irritable Bowel Syndrome as Second-Line Treatment [ATLANTIS]) was conducted at 55 general practices in England. Eligible participants were aged 18 years or older, with Rome IV IBS of any subtype, and ongoing symptoms (IBS Severity Scoring System [IBS-SSS] score ≥75 points) despite dietary changes and first-line therapies, a normal full blood count and C-reactive protein, negative coeliac serology, and no evidence of suicidal ideation. Participants were randomly assigned (1:1) to low-dose oral amitriptyline (10 mg once daily) or placebo for 6 months, with dose titration over 3 weeks (up to 30 mg once daily), according to symptoms and tolerability. Participants, their general practitioners, investigators, and the analysis team were all masked to allocation throughout the trial. The primary outcome was the IBS-SSS score at 6 months. Effectiveness analyses were according to intention-to-treat; safety analyses were on all participants who took at least one dose of the trial medication. This trial is registered with the ISRCTN Registry (ISRCTN48075063) and is closed to new participants. FINDINGS: Between Oct 18, 2019, and April 11, 2022, 463 participants (mean age 48·5 years [SD 16·1], 315 [68%] female to 148 [32%] male) were randomly allocated to receive low-dose amitriptyline (232) or placebo (231). Intention-to-treat analysis of the primary outcome showed a significant difference in favour of low-dose amitriptyline in IBS-SSS score between groups at 6 months (-27·0, 95% CI -46·9 to -7·10; p=0·0079). 46 (20%) participants discontinued low-dose amitriptyline (30 [13%] due to adverse events), and 59 (26%) discontinued placebo (20 [9%] due to adverse events) before 6 months. There were five serious adverse reactions (two in the amitriptyline group and three in the placebo group), and five serious adverse events unrelated to trial medication. INTERPRETATION: To our knowledge, this is the largest trial of a tricyclic antidepressant in IBS ever conducted. Titrated low-dose amitriptyline was superior to placebo as a second-line treatment for IBS in primary care across multiple outcomes, and was safe and well tolerated. General practitioners should offer low-dose amitriptyline to patients with IBS whose symptoms do not improve with first-line therapies, with appropriate support to guide patient-led dose titration, such as the self-titration document developed for this trial. FUNDING: National Institute for Health and Care Research Health Technology Assessment Programme (grant reference 16/162/01).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
RUBIN, D. B. (1976) · Biometrika · doi:10.1093/biomet/63.3.581 · Cited by 9,925
Lacy, B. E., Mearin, F., Chang, L., Chey, W. D., Lembo, A. J., Simren, M., & Spiller, R. (2016) · Gastroenterology · doi:10.1053/j.gastro.2016.02.031 · Cited by 2,866
The Work and Social Adjustment Scale: a simple measure of impairment in functioning
Mundt, J. C., Marks, I. M., Shear, M. K., & Greist, J. M. (2002) · British Journal of Psychiatry · doi:10.1192/bjp.180.5.461 · Cited by 2,515
The PRECIS-2 tool: designing trials that are fit for purpose
Loudon, K., Treweek, S., Sullivan, F., Donnan, P., Thorpe, K. E., & Zwarenstein, M. (2015) · BMJ · doi:10.1136/bmj.h2147 · Cited by 1,846 · cited 1×
“In terms of where trials lie on the pragmatic-explanatory continuum, ATLANTIS leaned strongly towards the pragmatic end for six of the nine PRECIS-2 criteria, 48 including eligibility, setting, organisation, flexibility of delivery of the intervention, primary outcome, and primary analysis.”
FRANCIS, C. Y., MORRIS, J., & WHORWELL, P. J. (1997) · Alimentary Pharmacology & Therapeutics · doi:10.1046/j.1365-2036.1997.142318000.x · Cited by 1,708
Peery, A. F., Crockett, S. D., Murphy, C. C., Lund, J. L., Dellon, E. S., Williams, J. L., Jensen, E. T., Shaheen, N. J., Barritt, A. S., Lieber, S. R., et al. (2019) · Gastroenterology · doi:10.1053/j.gastro.2018.08.063 · Cited by 1,619
Placebos without Deception: A Randomized Controlled Trial in Irritable Bowel Syndrome
Kaptchuk, T. J., Friedlander, E., Kelley, J. M., Sanchez, M. N., Kokkotou, E., Singer, J. P., Kowalczykowski, M., Miller, F. G., Kirsch, I., & Lembo, A. J. (2010) · PLoS ONE · doi:10.1371/journal.pone.0015591 · Cited by 900 · cited 2×
“52,53 Other possible explanations include provision of the British Dietetic Association dietary advice sheet to all participants, regular follow-up, usual general practitioner care throughout, and telephone calls from a research nurse to assist with dose titration and trial medication reissue.”
Oka, P., Parr, H., Barberio, B., Black, C. J., Savarino, E. V., & Ford, A. C. (2020) · The Lancet Gastroenterology & Hepatology · doi:10.1016/s2468-1253(20)30217-x · Cited by 882 · cited 1×
“%] in the amitriptyline group and ten [4”
Self-citationFord, A. C., Sperber, A. D., Corsetti, M., & Camilleri, M. (2020) · The Lancet · doi:10.1016/s0140-6736(20)31548-8 · Cited by 818
Self-citationDrossman, D. A., Toner, B. B., Whitehead, W. E., Diamant, N. E., Dalton, C. B., Duncan, S., Emmott, S., Proffitt, V., Akman, D., Frusciante, K., et al. (2003) · Gastroenterology · doi:10.1016/s0016-5085(03)00669-3 · Cited by 614 · cited 1×
“Adverse events with amitriptyline related mainly to its known anticholinergic effects, including dry mouth (90 [54”
Cited by
An evidence-based update on the diagnosis and management of irritable bowel syndrome
Black, C. J., & Ford, A. C. (2025) · Expert Review of Gastroenterology & Hepatology · doi:10.1080/17474124.2025.2455586 · Cited by 27
Self-citationChronic, Noninfectious Diarrhea: A Review
Singh, P., Lee, A., Sheth, N. M., & Chey, W. D. (2026) · JAMA · doi:10.1001/jama.2026.0872 · Cited by 13
Metadata
- Authors
- Ford, A. C., Wright-Hughes, A., Alderson, S. L., Ow, P.-L., Ridd, M. J., Foy, R., Bianco, G., Bishop, F. L., Chaddock, M., Cook, H., Cooper, D., Fernandez, C., Guthrie, E. A., Hartley, S., Herbert, A., Howdon, D., Muir, D. P., Nath, T., Newman, S., Smith, T., Taylor, C. A., Teasdale, E. J., Thornton, R., Farrin, A. J., Everitt, H. A., Ford, A. C., Wright-Hughes, A., Alderson, S. L., Ow, P.-L., Ridd, M. J., Foy, R., Barratt, M., Bianco, G., Bishop, F. L., Brindle, R., Brown, S., Chaddock, M., Christodoulou, A., Cook, H., Cooper, D., Day, F., Dowse, A., Durnell, J., Emmerson, J., Fellows, A., Fernandez, C., Guthrie, E. A., Hartley, S., Herbert, A., Hindmarch, D., Howdon, D., Malik, A., Morris, T., Muir, D. P., Longo, R., Lopes Goncalves Graca, S., Nath, T., Newman, S., Parker, C., Smith, T., Taylor, C. A., Teasdale, E. J., Thornton, R., Tubeuf, S., West, A., Williamson, E.-J., Farrin, A. J., & Everitt, H. A.
- Venue
- The Lancet
- Publisher
- Elsevier BV
- Published
- 2023-11
- Volume
- 402
- Issue
- 10414
- Pages
- 1773-1785
- ISSN
- 0099-5355 (ISSN-L)
- 0140-6736
- OpenAlex
- W4387666446
- Cited by
- 146
- References
- 31
- FWCI
- 34.33
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Amitriptyline at Low-Dose and Titrated for Irritable Bowel Syndrome as Second-Line Treatment in primary care (ATLANTIS): a randomised, double-blind, placebo-controlled, phase 3 trial. https://app.cochat.ai/papers/10.1016/s0140-6736(23)01523-4
- The paper
- Ford, A. C., Wright-Hughes, A., Alderson, S. L., Ow, P.-L., Ridd, M. J., Foy, R., Bianco, G., Bishop, F. L., Chaddock, M., Cook, H., Cooper, D., Fernandez, C., Guthrie, E. A., Hartley, S., Herbert, A., Howdon, D., Muir, D. P., Nath, T., Newman, S., . . . Everitt, H. A. (2023). Amitriptyline at Low-Dose and Titrated for Irritable Bowel Syndrome as Second-Line Treatment in primary care (ATLANTIS): a randomised, double-blind, placebo-controlled, phase 3 trial. The Lancet. https://doi.org/10.1016/s0140-6736(23)01523-4
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.